<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00352443</url>
  </required_header>
  <id_info>
    <org_study_id>S0528</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S0528</secondary_id>
    <nct_id>NCT00352443</nct_id>
  </id_info>
  <brief_title>S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989) and Everolimus (RAD001) in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lapatinib and everolimus may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth. Everolimus may also stop the growth of cancer cells by&#xD;
      blocking blood flow to the cancer. Giving lapatinib together with everolimus may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib and&#xD;
      everolimus in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Estimate the maximum tolerated dose (MTD) of lapatinib and everolimus in patients with&#xD;
           advanced solid tumors or non-Hodgkin's lymphoma. (Part I)&#xD;
&#xD;
        -  Investigate the pharmacokinetics of everolimus and lapatinib (when given alone and in&#xD;
           combination) at the MTD determined in Part I. (Part II)&#xD;
&#xD;
        -  Investigate the effects of everolimus and lapatinib (when given alone and in&#xD;
           combination) on serum levels of vascular endothelial growth factor (VEGF), basic&#xD;
           fibroblast growth factor (bFGF), matrix metalloproteinase (MMP)-2 and MMP-9,&#xD;
           interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α). (Part II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study followed by a randomized study. Initial&#xD;
      patients enrolled on the study are treated in part I. After the maximum tolerated dose (MTD)&#xD;
      is determined in part I, subsequent patients are enrolled and treated in part II.&#xD;
&#xD;
        -  Part I: Patients receive oral everolimus and oral lapatinib once daily on days 1-28.&#xD;
           Courses repeat every 28 days in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of everolimus and lapatinib until the MTD is&#xD;
      determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience&#xD;
      dose-limiting toxicity.&#xD;
&#xD;
        -  Part II: Patients are randomized to 1 of 2 treatment arms. Everolimus and lapatinib are&#xD;
           administered at the MTD determined in part I.&#xD;
&#xD;
             -  Arm I: Patients receive oral everolimus once daily on days 1-28. Patients also&#xD;
                receive oral lapatinib once daily on days 8-28 during the first course and on days&#xD;
                1-28 during all subsequent courses. Courses repeat every 28 days in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
             -  Arm II: Patients receive oral lapatinib once daily on days 1-28. Patients also&#xD;
                receive oral everolimus once daily on days 8-28 during the first course and on days&#xD;
                1-28 during all subsequent courses. Courses repeat every 28 days in the absence of&#xD;
                disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients in part II undergo blood collection periodically for correlative biomarker and&#xD;
      pharmacokinetic studies.&#xD;
&#xD;
      After finishing treatment, patients are followed periodically for 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of lapatinib and everolimus (Part I)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Part II)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>everolimus/lapatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)</description>
    <arm_group_label>everolimus/lapatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily</description>
    <arm_group_label>everolimus/lapatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced solid tumor or non-Hodgkin's&#xD;
             lymphoma for which no curative options exist&#xD;
&#xD;
          -  Measurable or nonmeasurable disease&#xD;
&#xD;
          -  Patients with brain metastases who require corticosteroids or anticonvulsants must be&#xD;
             on a stable or decreasing dose of corticosteroids and seizure free for 30 days prior&#xD;
             to study entry&#xD;
&#xD;
               -  Patients with known brain metastases must have had brain irradiation (whole brain&#xD;
                  or gamma knife)&#xD;
&#xD;
                    -  No untreated (non-irradiated) brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases&#xD;
             are present)&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Cardiac ejection fraction normal by echocardiogram or MUGA&#xD;
&#xD;
          -  Able to swallow enteral medications&#xD;
&#xD;
          -  No feeding tubes&#xD;
&#xD;
          -  No intractable nausea or vomiting&#xD;
&#xD;
          -  No gastrointestinal (GI) tract disease resulting in an inability to take oral&#xD;
             medication&#xD;
&#xD;
          -  No current active hepatic or biliary disease with the exception of Gilbert's syndrome&#xD;
             or asymptomatic gallstones&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
          -  No requirement for IV alimentation&#xD;
&#xD;
          -  No uncontrolled inflammatory GI disease (e.g., Crohn's disease, ulcerative colitis)&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to lapatinib or everolimus, including other quinazoline&#xD;
             compounds, such as gefitinib and erlotinib, or other rapamycins, such as sirolimus and&#xD;
             temsirolimus&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No concurrent uncontrolled illness, including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Myocardial infarction or cerebrovascular accident within the past 3 months&#xD;
&#xD;
               -  Uncontrolled diarrhea&#xD;
&#xD;
               -  Psychiatric illness or social situation that would preclude compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to undergo pharmacokinetic (PK) sampling and blood collection for PK and&#xD;
             correlative studies (for patients enrolled in part II)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior lapatinib or everolimus&#xD;
&#xD;
          -  No prior surgical procedures affecting absorption&#xD;
&#xD;
          -  More than 14 days since prior major surgery, chemotherapy (42 days for nitrosoureas or&#xD;
             mitomycin C), or radiotherapy&#xD;
&#xD;
          -  More than 28 days since prior investigational agents&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent CYP3A4 inducers&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent herbal or dietary supplements&#xD;
&#xD;
          -  No concurrent chemotherapy, hormone therapy, radiotherapy, immunotherapy, live&#xD;
             vaccines or any other anticancer therapy&#xD;
&#xD;
               -  Concurrent luteinizing hormone-releasing hormone agonists allowed&#xD;
&#xD;
               -  Concurrent bisphosphonates or epoetin alfa or its analogue allowed&#xD;
&#xD;
          -  No concurrent gastric H2 blockers (e.g., cimetidine, ranitidine, nizatidine,&#xD;
             famotidine) or proton pump inhibitors (e.g., omeprazole, esomeprazole, rabeprazole,&#xD;
             pantoprazole, or lansoprazole)&#xD;
&#xD;
               -  Antacids allowed provided they are not administered within 1 hour before and&#xD;
                  after lapatinib&#xD;
&#xD;
          -  No concurrent glucocorticoids or immunosuppressants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shirish M. Gadgeel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia M. LoRusso, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089-9181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center at UC Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cancer Center at University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195-6043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hoban CJ, Hoering A, Synold TW, et al.: Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528. [Abstract] J Clin Oncol 27 (Suppl 15): A-3553, 2009.</citation>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 13, 2006</study_first_submitted>
  <study_first_submitted_qc>July 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2006</study_first_posted>
  <last_update_submitted>March 5, 2015</last_update_submitted>
  <last_update_submitted_qc>March 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

